Search PubMed⌕ Search

PubMed · 12723749

Ibuprofen overdose.

Abstract

Enquiries about the management of patients possibly suffering from ibuprofen overdose account for over 5% of the total enquiry workload of the London Centre of the United Kingdom National Poisons Information Service. Unlike overdose with aspirin and paracetamol, no additional pathophysiological findings have been reported in ibuprofen overdose and all the demonstrated toxic effects relate to its known pharmacological actions and the effects of accumulation of the two acidic metabolites, 2-hydroxyibuprofen and 2-carboxylibuprofen. The most striking finding in reported cases is that the great majority of patients suffer no or only mild symptoms. In one series of 1,033 enquiries involving ingestion of ibuprofen alone, 705 (65%) patients were asymptomatic; 199 (18%) experienced mild symptoms; and 23 (2%) experienced moderate symptoms. We are aware of only seven case reports of fatal overdose with ibuprofen and in each case there are complicating factors related to other drugs and/or other disease processes. The management of ibuprofen overdose is generally straightforward and can be related to the dose ingested. Initial findings suggest even less evidence for toxicity associated with modified release formulations than with the conventional tablets. There is at present no reason to be concerned that co-ingestion of ethanol increases the risk of toxicity from ibuprofen overdose. Ibuprofen overdose is common but serious toxic effects are unusual and guidelines for treatment are straightforward.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Glyn Volans, Jane Monaghan, Mark Colbridge. 2003. Ibuprofen overdose.. https://pubmed.ncbi.nlm.nih.gov/12723749/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Can we reduce disease burden from osteoarthritis?

The comparison of disparate interventions for the prevention and management of osteoarthritis (OA) is limited by the quality and quantity of published efficacy studies and the use of disparate measures for reporting clinical trial outcomes. The "transfer to utility" technique was used to translate published trial outcomes into a health-related quality-of-life (utility) scale, creating a common metric which supported comparisons between disparate interventions. Total hip replacement (THR) and total knee replacement (TKR) surgery were the most effective treatments and also highly cost-effective, at estimated cost per quality-adjusted life-year (QALY) of 7500 dollars for THR and 10000 dollars for TKR (best estimate). Other apparently highly cost-effective interventions were exercise and strength training for knee OA (< 5000 dollars/QALY), knee bracing, and use of capsaicin or glucosamine sulfate (< 10000 dollars/QALY). The cost per QALY estimates of non-specific and COX-2 inhibitor non-steroidal anti-inflammatory drugs were affected by treatment-related deaths and highly sensitive to the discounting of life-years lost. OA interventions that have been shown to be ineffective (eg, arthroscopy) are targets for redistribution of healthcare resources. OA interventions which lack efficacy studies (eg, prevention programs) require further research to assist priority setting. The application of the Health-sector Wide model to OA demonstrates its role as an evidence-based model that can be successfully applied to identify marginal interventions - those to be expanded and contracted to reduce the expected burden of disease, within current healthcare resources.

Anti-Inflammatory Agents, Non-Steroidal↗